查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948933

肺動脈瓣膜人工系統市場（按產品類型、材料類型和最終用戶分類），全球預測，2026-2032年

Artificial Pulmonary Valve System Market by Product Type, Material Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工肺動脈瓣膜系統市場價值將達到 13.8 億美元，到 2026 年將成長至 15.4 億美元，到 2032 年將達到 34.5 億美元，複合年成長率為 13.95%。

關鍵市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 15.4億美元
預測年份 2032 34.5億美元
複合年成長率 (%) 13.95%

提供人工肺動脈瓣系統的臨床、技術和商業性背景，以指導經營團隊的策略優先排序。

人工肺動脈瓣膜系統的發展現狀取決於外科手術創新、微創心臟治療以及不斷變化的患者群體。過去十年，手術流程的改進、生物材料的進步，以及影像技術的提升和病患選擇標準的最佳化，都大大拓展了右心室流出道重組的治療選擇。因此，決策者不僅需要評估器材的效能，還必須考慮臨床路徑、醫院準備、醫保報銷環境以及長期耐久性等因素。

變革性轉變重塑肺動脈瓣膜治療領域的設備開發、臨床應用與商業策略

肺動脈瓣領域正經歷多重變革，這些變革正在重新定義器材的研發、評估和應用方式。首先，微創介入治療日益受到青睞，推動了經導管治療的發展；同時，生物瓣膜材料的改進和抗鈣化治療的進步延長了器械的使用壽命。這些技術進步降低了再次介入率，並影響心臟團隊對年輕患者終身管理策略的採納。

2025年美國關稅對肺動脈瓣膜系統供應鏈、定價結構及商業性進入的累積影響

2025年美國關稅調整對製造商和醫療保健系統產生了多方面的營運和商業影響。對某些醫療零件徵收的進口關稅增加了依賴國際採購的專用原料和成品組件的醫療器材的到岸成本。為應對這一變化，許多製造商加快了近岸外包計劃，轉移了部分組裝業務，並重新談判了供應商契約，以緩解利潤率下降。

關鍵細分洞察揭示了產品、材料、最終用戶、分銷管道和年齡層在臨床需求、技術契合度和商業性機會方面的交集。

在考慮產品類型時，區分外科植入式肺動脈瓣膜和經導管肺動脈瓣膜至關重要。外科植入式瓣膜分為生物瓣膜和機械瓣膜，而經導管瓣膜則採用球囊擴張型和自擴張式技術，這些技術決定了臨床工作流程、培訓要求和醫院的資金投入。就材料類型而言，與生物瓣膜相比，機械瓣膜和聚合物瓣膜在耐用性和抗凝血效果方面各有優劣。生物瓣膜的進一步差異在於其所用組織為心包組織還是豬組織，這會影響血流動力學和長期鈣化。從最終用戶的觀點，門診手術中心、醫院和專科診所各自專注於不同的價值因素。門診中心通常強調手術量和縮短住院通訊協定，醫院強調多學科診療和複雜病例處理能力，而專科診所通常作為長期後續觀察和器械監測的轉診中心。

區域性洞察，聚焦全球市場在採用曲線、法規環境和報銷趨勢方面的差異

在美洲，成熟的臨床網路和集中式卓越中心支援新型經導管解決方案的快速應用。採購流程深受醫院藥品清單和全面醫療系統評估的影響。在該地區，對已證實的長期療效和易於整合到現有導管檢查室基礎設施的重視，決定了產品上市的順序以及早期商業化階段所產生的證據的性質。同時，在歐洲、中東和非洲，監管路徑和報銷模式各不相同，國家衛生技術評估和區域採購聯盟可能會加速或延緩產品的普及。在該地區的許多國家，療效比較數據和成本效益分析是產品被廣泛採用的關鍵因素。

主要企業洞察：分析領先開發商和新參與企業的競爭定位、平台策略和差異化路徑

肺動脈瓣膜領域的競爭優勢取決於平台的多功能性、臨床證據的深度以及支持全面培訓和服務模式的能力。投資於模組化輸送平台和多瓣膜技術的領先開發商正受益於交叉銷售機會，並減輕其機構客戶在特定手術方面的培訓負擔。新參與企業則透過在生物材料、計算尺寸演算法和簡化輸送系統方面的專注創新來實現差異化，旨在縮短手術時間並降低對操作者的依賴性。

為產業領導者提供的實用建議：加速臨床應用、增強市場進入並最佳化長期價值交付

行業領導者應優先考慮整合隨機數據和真實世界註冊研究，以證明藥物在不同患者群體中的療效和長期持久性。使臨床試驗設計與支付方的證據要求保持一致，將加快報銷談判，並縮短商業性報銷決策時間。同時，投資於模組化平台架構和交付系統，最大限度地降低學習曲線，將有助於醫院採納並降低培訓成本。在商業性，採用混合分銷策略，將與患者量高的中心直接合作，並與患者量低地區的經銷商網路結合，將最佳化覆蓋範圍和資源配置。

本報告所採用的調查方法支撐了分析的嚴謹性、資料三角驗證和檢驗過程。

本摘要的分析整合了多方面的證據，以確保分析的嚴謹性和實際應用價值。透過對臨床意見領袖、醫療設備開發商和醫療系統採購負責人的初步調查，我們對醫療器材的推廣應用促進因素、培訓需求和支付方參與度進行了定性評估。此外，我們也查閱了二級資訊來源，以了解技術趨勢、監管動態和材料科學進展的背景。最後，我們將這些發現與公開的臨床試驗註冊庫和同儕審查文獻進行交叉檢驗，以確認其與現有的臨床證據相符。

結論：針對相關人員，制定了旨在改善臨床療效和維持商業性成長動能的綜合策略要務和後續步驟。

人工肺動脈瓣膜系統的市場格局呈現出一系列引人入勝卻又錯綜複雜的機遇，唯有整合創新技術、實證醫學證據和市場進入策略，方能把握機會。經導管輸送技術和生物材料的進步正在拓展治療選擇，而區域監管環境和報銷系統則要求企業制定量身定做的商業策略。能夠將模組化產品平台、可靠的臨床數據和穩健的供應鏈結合的企業，將最有可能獲得持續的競爭優勢。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 肺動脈瓣膜人工系統市場（依產品類型分類）

  • 外科植入式肺動脈瓣
    • 生物瓣膜
    • 機械閥
  • 經導管肺動脈瓣膜
    • 球囊擴張型閥
    • 自膨脹閥

9. 依材料類型分類的肺動脈瓣膜人工系統市場

  • 機械閥
  • 聚合物閥
  • 生物瓣膜
    • 心包組織
    • 豬組織

第10章 肺動脈瓣膜人工系統市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 各地區人工肺動脈瓣膜系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 肺動脈瓣膜人工系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國肺動脈瓣膜人工系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

14. 美國肺動脈瓣膜人工系統市場

第15章：中國人工肺動脈瓣膜系統市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Affluent Medical, Inc.
  • Anteris Technologies Pty Ltd
  • Artivion, Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Braile Biomedica Industria e Comercio SA
  • Colibri Heart Valve, LLC
  • Corcym Srl
  • Edwards Lifesciences Corporation
  • Foldax, Inc.
  • Innovalve Bio Medical Ltd.
  • JenaValve Technology, Inc.
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort CardioFlow Medtech Corporation
  • Peijia Medical Devices Co., Ltd.
  • PolyVascular, Inc.
  • TTK Healthcare Limited
  • Venus MedTech（Hangzhou）Inc.
  • Xeltis NV
Product Code: MRR-4F7A6D4FB8F1

The Artificial Pulmonary Valve System Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.54 billion in 2026, with a CAGR of 13.95%, reaching USD 3.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 3.45 billion
CAGR (%) 13.95%

Framing the clinical, technological, and commercial context for artificial pulmonary valve systems to guide executive strategic prioritization

The artificial pulmonary valve system landscape sits at the intersection of surgical innovation, minimally invasive cardiology, and evolving patient demographics. Over the past decade, procedural refinements and biomaterial advances have combined with improved imaging and patient selection to expand therapeutic options for right ventricular outflow tract reconstruction. Consequently, decision-makers must evaluate not only device performance but also clinical pathways, hospital readiness, reimbursement environments, and long-term durability considerations.

This executive summary synthesizes core themes relevant to manufacturers, healthcare providers, and investor stakeholders. It highlights technological inflection points, regulatory and policy pressures, and shifting clinical adoption patterns. The document is designed to orient executives to the most consequential forces shaping development priorities and market access strategies.

Moving forward, readers should interpret the findings through a pragmatic lens: device value is determined by clinical outcomes, procedural efficiency, and the ability to integrate into established care pathways. Accordingly, the subsequent sections emphasize strategic implications, segmentation-specific insights, and actionable recommendations to align R&D, commercial, and regulatory efforts with evolving stakeholder expectations.

Transformative Shifts Reshaping Device Development, Clinical Adoption, and Commercial Strategy in Pulmonary Valve Therapy

The pulmonary valve domain is experiencing multiple simultaneous shifts that are redefining how devices are developed, evaluated, and adopted. First, the growing preference for less invasive interventions has accelerated interest in transcatheter solutions, while refinements in bioprosthetic materials and anti-calcification treatments are extending device longevity. These technical improvements reduce reintervention rates and influence adoption among heart teams that weigh lifetime management strategies for younger patients.

Second, advanced imaging and computational modeling are enabling more precise sizing and procedural planning, which in turn lowers complication rates and expands eligibility for patients with complex right ventricular outflow tract anatomies. As a result, centers of excellence are increasingly capturing higher volumes and acting as early adopters that validate performance claims in real-world settings.

Third, the competitive landscape is being reshaped by modular product architectures and platform strategies that emphasize shared delivery systems and incremental valve upgrades. This approach shortens product cycles and changes commercialization dynamics, with after-sales services and training becoming central to customer retention. Finally, policy and tariff shifts in certain jurisdictions are prompting supply chain diversification and reconsideration of global sourcing strategies, which has downstream implications for cost structures and pricing models.

Cumulative Impact of United States Tariffs Enacted in 2025 on Supply Chains, Pricing Structures, and Commercial Access for Pulmonary Valve Systems

Tariff adjustments introduced in the United States during 2025 have produced a range of operational and commercial effects for manufacturers and health systems. Import duties on certain medical components increased landed costs for devices that rely on specialized raw materials or finished subassemblies sourced internationally. In response, many manufacturers accelerated nearshoring initiatives, relocated select assembly operations, and renegotiated supplier agreements to mitigate margin compression.

These supply chain responses generated short-term logistical complexity, including inventory rebalancing and expanded use of bonded warehouses to smooth fulfillment to hospitals and specialty clinics. Over time, organizations that strategically diversified supplier bases and invested in local manufacturing resilience improved their ability to offer competitive pricing while preserving service levels. Clinically, some hospital procurement groups delayed non-urgent capital purchases as they reassessed total cost of ownership under the new tariff realities, prompting manufacturers to propose flexible pricing constructs or managed entry agreements.

Concurrently, payers and health systems emphasized demonstration of value through outcomes and cost-per-procedure analyses, which increased the importance of post-market evidence generation and outcomes registries. In aggregate, the tariff changes catalyzed a reassessment of global manufacturing footprints and commercial models, with durable advantages accruing to organizations that combined operational agility with compelling clinical evidence.

Key Segmentation Insights That Reveal Where Clinical Need, Technology Fit, and Commercial Opportunity Converge Across Product, Material, End User, Distribution, and Age Cohorts

When examining product type, it is critical to differentiate surgically implanted pulmonary valves from transcatheter pulmonary valves, recognizing that surgically implanted options split into bioprosthetic and mechanical valves while transcatheter offerings are characterized by balloon expandable and self expandable technologies; this distinction drives divergent clinical workflows, training requirements, and hospital capital needs. Regarding material type, mechanical valves and polymer valves present distinct durability and anticoagulation trade-offs compared with tissue valves, with tissue options further differentiated by pericardial tissue and porcine tissue choices that affect hemodynamics and long-term calcification profiles. From the end user perspective, ambulatory surgical centers, hospitals, and specialty clinics each prioritize different value drivers: ambulatory centers emphasize throughput and shorter length-of-stay protocols, hospitals focus on multidisciplinary care coordination and complex-case capability, and specialty clinics often serve as referral hubs for longitudinal follow-up and device surveillance.

Distribution channel dynamics matter because direct sales arrangements allow manufacturers to maintain clinical relationships and provide integrated training, whereas distributor sales offer broader geographic reach and inventory handling that may suit smaller suppliers. Age group segmentation reveals that adult and pediatric populations demand tailored device characteristics and follow-up strategies; the adult cohort subdivides into geriatric, middle aged, and young adult segments, each with unique comorbidity profiles and life-expectancy considerations, while the pediatric cohort subclasses into adolescent, infant, and neonatal groups with distinct anatomical constraints and growth-related management imperatives. Integrating these segmentation lenses clarifies where design priorities, clinical evidence, and commercial investments will most effectively yield adoption and improved patient outcomes.

Regional Insights That Highlight Differential Adoption Curves, Regulatory Environments, and Reimbursement Dynamics Across Global Markets

In the Americas, established clinical networks and concentrated centers of excellence support rapid uptake of novel transcatheter solutions, with procurement processes that are highly influenced by hospital formularies and integrated health system evaluations. This region shows a preference for proof of long-term outcomes and ease of integration into existing cath lab infrastructures, which shapes the sequencing of product launches and the nature of evidence generated during early commercialization phases. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory pathways and reimbursement models where national-level health technology assessments and regional procurement consortia can either accelerate or delay access; in many countries within this region, comparative effectiveness data and cost-effectiveness narratives become decisive for mainstream adoption.

Asia-Pacific markets are characterized by heterogeneous market maturity, ranging from advanced tertiary centers in urban hubs to rapidly developing specialty networks; these markets often emphasize scalable manufacturing partnerships and competitive pricing structures, while clinical opinion leaders in major centers can drive regional adoption through high-visibility case series and training programs. Across all regions, a common theme is the increasing importance of localized clinical evidence and reimbursement strategies tailored to national payment practices, which directly influence the sequencing of market entry and resource allocation for commercial operations.

Key Companies Insights That Distill Competitive Positioning, Platform Strategies, and Differentiation Pathways Among Leading Developers and New Entrants

Competitive positioning in the pulmonary valve domain is being defined by platform versatility, clinical evidence depth, and the ability to support comprehensive training and service models. Leading developers that have invested in modular delivery platforms and multi-valve footprints are benefiting from cross-selling opportunities and lower per-procedure training burdens for institutional customers. New entrants are differentiating through focused innovations in biomaterials, computational sizing algorithms, and simplified delivery systems aimed at reducing procedure time and operator dependency.

Strategic partnerships and licensing arrangements are common, particularly where technology gaps exist around imaging integration or proprietary anti-calcification treatments. Firms that align commercialization strategies with robust post-market surveillance and registry participation improve their credibility with cardiothoracic surgeons and interventional cardiologists. Moreover, companies that establish flexible commercial models-combining direct sales for flagship accounts with distributor partnerships in lower-volume territories-tend to achieve broader geographic penetration while conserving commercial expenditures. Overall, the competitive frontier centers on delivering durable clinical outcomes, streamlined procedural workflows, and demonstrable cost-effectiveness to health systems.

Actionable Recommendations for Industry Leaders to Accelerate Clinical Adoption, Strengthen Market Access, and Optimize Long-Term Value Delivery

Industry leaders should prioritize integrated evidence generation that couples randomized data with real-world registries to demonstrate both efficacy and long-term durability in diverse patient cohorts. Aligning clinical trial design with payer evidence needs facilitates faster reimbursement dialogues and reduces time to commercial reimbursement decisions. In parallel, investing in modular platform architectures and delivery systems that minimize learning curves will ease hospital adoption and reduce training costs. Commercially, a hybrid distribution strategy that combines direct engagement at high-volume centers with distributor networks in lower-volume geographies optimizes reach and resource allocation.

Operationally, companies should pursue supply chain resilience by diversifying suppliers, qualifying secondary manufacturing sites, and establishing contingencies for tariff or trade disruptions. Finally, manufacturers must collaborate proactively with clinical leaders to develop standardized care pathways and device surveillance protocols that enhance patient outcomes and generate the type of longitudinal data that payers and providers value. By executing on these recommendations, organizations can secure sustainable market positions while delivering measurable benefits to patients and health systems.

Research Methodology That Underpins the Analytical Rigor, Data Triangulation, and Validation Processes Employed in the Report

The analysis underpinning this summary combines multiple evidence streams to ensure analytical rigor and practical relevance. Primary research with clinical opinion leaders, device developers, and health system procurement professionals informed qualitative assessments of adoption drivers, training needs, and payer interactions. Secondary sources were reviewed to contextualize technological trends, regulatory developments, and material science advances; these findings were cross-validated against publicly available clinical trial registries and peer-reviewed literature to ensure alignment with established clinical evidence.

In addition, the methodology incorporated scenario analysis to evaluate the operational and commercial implications of supply chain disruptions and policy changes. Validation workshops with independent clinicians and industry advisors were convened to test key assumptions and refine strategic implications. Throughout the process, emphasis was placed on triangulation of insights, transparency in assumptions, and clear articulation of uncertainty to support confident decision-making by executive stakeholders.

Conclusion: Synthesis of Strategic Imperatives and Next Steps for Stakeholders Focused on Improving Clinical Outcomes and Sustaining Commercial Momentum

The artificial pulmonary valve system landscape presents a compelling but complex set of opportunities that reward integrated strategies across innovation, evidence generation, and market access. Technological progress in transcatheter delivery and biomaterials is expanding therapeutic options, while regional regulatory and reimbursement differences require tailored commercial tactics. Organizations that couple modular product platforms with robust clinical data and resilient supply chains will be best positioned to capture durable advantages.

Looking ahead, stakeholders should prioritize investments that reduce procedural complexity, enhance long-term device performance, and generate the localized evidence payers require for reimbursement. Building collaborative relationships with centers of excellence and engaging in post-market surveillance will accelerate trust and broaden adoption. Ultimately, success will hinge on aligning product development with demonstrable improvements in patient outcomes and cost-effectiveness, thereby securing both clinical credibility and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Pulmonary Valve System Market, by Product Type

  • 8.1. Surgically Implanted Pulmonary Valve
    • 8.1.1. Bioprosthetic Valve
    • 8.1.2. Mechanical Valve
  • 8.2. Transcatheter Pulmonary Valve
    • 8.2.1. Balloon Expandable Valve
    • 8.2.2. Self Expandable Valve

9. Artificial Pulmonary Valve System Market, by Material Type

  • 9.1. Mechanical Valve
  • 9.2. Polymer Valve
  • 9.3. Tissue Valve
    • 9.3.1. Pericardial Tissue
    • 9.3.2. Porcine Tissue

10. Artificial Pulmonary Valve System Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Artificial Pulmonary Valve System Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Artificial Pulmonary Valve System Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Artificial Pulmonary Valve System Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Artificial Pulmonary Valve System Market

15. China Artificial Pulmonary Valve System Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Affluent Medical, Inc.
  • 16.7. Anteris Technologies Pty Ltd
  • 16.8. Artivion, Inc.
  • 16.9. BIOTRONIK SE & Co. KG
  • 16.10. Boston Scientific Corporation
  • 16.11. Braile Biomedica Industria e Comercio S.A.
  • 16.12. Colibri Heart Valve, LLC
  • 16.13. Corcym S.r.l.
  • 16.14. Edwards Lifesciences Corporation
  • 16.15. Foldax, Inc.
  • 16.16. Innovalve Bio Medical Ltd.
  • 16.17. JenaValve Technology, Inc.
  • 16.18. Labcor Laboratorios Ltda
  • 16.19. Lepu Medical Technology Co., Ltd.
  • 16.20. LivaNova PLC
  • 16.21. Medtronic plc
  • 16.22. Meril Life Sciences Pvt. Ltd.
  • 16.23. MicroPort CardioFlow Medtech Corporation
  • 16.24. Peijia Medical Devices Co., Ltd.
  • 16.25. PolyVascular, Inc.
  • 16.26. TTK Healthcare Limited
  • 16.27. Venus MedTech (Hangzhou) Inc.
  • 16.28. Xeltis NV

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)